$2.685
-0.044 (-1.65%)At close
Technical Sentiment
Overall Consensus
Technical Analysis Consensus
Moving Average Consensus
Apimeds Pharmaceuticals US Inc (APUS) Moving Averages Convergence Divergence (MACD) indicator is -0.38, suggesting APUS is Strong sell.
Apimeds Pharmaceuticals US Inc (APUS) 20-Day simple moving average is 3.42, while Apimeds Pharmaceuticals US Inc (APUS) share price is $—, making it Sell.
Apimeds Pharmaceuticals US Inc (APUS) 60-Day simple moving average is 3.68, while Apimeds Pharmaceuticals US Inc (APUS) share price is $—, making it Sell.
Technical Analysis for APUS
AI Technical APUSAs of 2026-11-07, the technical board for Apimeds Pharmaceuticals US Inc (APUS) reads strong sell: 0 indicators are flashing buy, 9 are indicating sell, and 4 are neutral. Price at $2.68 sits below every tracked moving average (5-day, 10-day, 20-day, 60-day and 200-day).
Momentum readings: RSI stands at 39.849, MACD stands at -0.379 (Sell), Stochastic %K stands at 25.177, Stochastic %D stands at 25.486 and CCI stands at -81.466.
APUS trades below the 60-day SMA (3.68) and below the 200-day SMA (10.52). Immediate resistance sits at Classic R1 3.32, then R2 3.69. Support sits at Classic S1 2.48, then S2 2.02.
Apimeds Pharmaceuticals US Inc (APUS) Support & Resistance Level
Apimeds Pharmaceuticals US Inc (APUS) Technical Indicators
2026-11-07
| Name | Value |
|---|---|
| RSI_14 | 39.849 |
| STOCHk_14_3_3 | 25.177 |
| STOCHd_14_3_3 | 25.486 |
| CCI_20 | -81.466 |
| AO_5_34 | -1.348 |
| MOM_10 | -0.185 |
| MACD_12_26_9 | -0.379 |
Apimeds Pharmaceuticals US Inc (APUS) Relative Strength Index (RSI_14) is 39.849, creating a Neutral signal.
Apimeds Pharmaceuticals US Inc (APUS) Stochastic %K is 25.177, creating a Neutral signal.
Apimeds Pharmaceuticals US Inc (APUS) Stochastic %D is 25.486, creating a Neutral signal.
Apimeds Pharmaceuticals US Inc (APUS) CCI_20 is -81.466, creating a Neutral signal.
Apimeds Pharmaceuticals US Inc (APUS) Awesome Oscillator (AO) is -1.348, creating a Sell signal.
Apimeds Pharmaceuticals US Inc (APUS) Momentum (MOM) is -0.185, creating a Sell signal.
Apimeds Pharmaceuticals US Inc (APUS) Moving Average Convergence Divergence (MACD) is -0.379, creating a Sell signal.
Apimeds Pharmaceuticals US Inc (APUS) Moving Average
2026-11-07
| Period | Simple | Signal |
|---|---|---|
| MA_5 | 2.843 | Sell |
| MA_10 | 2.945 | Sell |
| MA_20 | 3.425 | Sell |
| MA_60 | 3.678 | Sell |
| MA_200 | 10.521 | Sell |
| MA_250 | 12.630 | Sell |
Apimeds Pharmaceuticals US Inc (APUS) 5-Day simple moving average is 2.843, while Apimeds Pharmaceuticals US Inc (APUS) share price is $, making it a Sell.
Apimeds Pharmaceuticals US Inc (APUS) 10-Day simple moving average is 2.945, while Apimeds Pharmaceuticals US Inc (APUS) share price is $, making it a Sell.
Apimeds Pharmaceuticals US Inc (APUS) 20-Day simple moving average is 3.425, while Apimeds Pharmaceuticals US Inc (APUS) share price is $, making it a Sell.
Apimeds Pharmaceuticals US Inc (APUS) 60-Day simple moving average is 3.678, while Apimeds Pharmaceuticals US Inc (APUS) share price is $, making it a Sell.
Apimeds Pharmaceuticals US Inc (APUS) 200-Day simple moving average is 10.521, while Apimeds Pharmaceuticals US Inc (APUS) share price is $, making it a Sell.
Apimeds Pharmaceuticals US Inc (APUS) 250-Day simple moving average is 12.630, while Apimeds Pharmaceuticals US Inc (APUS) share price is $, making it a Sell.
Related articles
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.